EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

β-Hydroxybutyrate Attenuates Cardiac Inflammation and Hepatic Fibrosis in Dahl Salt-Sensitive Rats

Satoyasu Ito iD, Eri Manabe, Toshiyuki Shikata, Kojiro Takamoto, Shuhei Kobuchi

Current Issues in Molecular Biology · 16.06.2026 · 48 (6) · 620

DOI: 10.3390/cimb48060620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 16.06.2026. Verfasst von Satoyasu Ito und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacy, Department of Pharmacy, School of Pharmacy, Hyogo Medical University, Kobe 650-8530, Japan. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertension remains a major driver of multi-organ damage, including cardiac remodeling and hepatic complications. The ketone body β-hydroxybutyrate (BHB) has emerged as a potential metabolic signaling molecule with anti-inflammatory properties. This study investigated whether BHB attenuates cardiac stress and hepatic injury in a salt-sensitive hypertensive model. Dahl salt-sensitive (DS) rats were fed a high-salt (HS) diet combined with a choline-deficient diet to induce cardiac inflammation and hepatic fibrosis. Rats received either BHB or a control vehicle. We found that BHB significantly suppressed hepatic lipid accumulation and fibrotic markers, including TGF-β and collagen III mRNA, even under severe dietary stress. In the heart, BHB attenuated the expression of inflammatory markers (TNF-α and ANP) despite the persistence of high systolic blood pressure. These results demonstrate that BHB exerts direct organ-protective effects through anti-inflammatory and anti-fibrotic actions that are independent of robust blood pressure reduction. Our findings suggest that BHB could be a promising metabolic intervention for managing multi-organ complications in hypertensive patients with metabolic comorbidities.

Schlagwörter

Stichwörter der Autor:innen

fibrosishypertensioninflammationliverβ-hydroxybutyrate

Autor:innen und Institutionen

  • Division of Clinical Pharmacy, Department of Pharmacy, School of Pharmacy, Hyogo Medical University, Kobe 650-8530, Japan.
  • Department of Cardiovascular and Renal Medicine, School of Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan.
  • Department of Pharmacy, Hyogo Medical University Hospital, Nishinomiya 663-8501, Japan.
  • Division of Pharmacology, Department of Pharmacy, School of Pharmacy, Hyogo Medical University, Kobe 650-8530, Japan.

ORCID-Profile: Satoyasu Ito

Zitieren

APA

Ito, S., Manabe, E., Shikata, T., Takamoto, K., & Kobuchi, S. (2026). β-Hydroxybutyrate Attenuates Cardiac Inflammation and Hepatic Fibrosis in Dahl Salt-Sensitive Rats. Current Issues in Molecular Biology, 48(6), 620. https://doi.org/10.3390/cimb48060620

Vancouver

Ito S, Manabe E, Shikata T, Takamoto K, Kobuchi S. β-Hydroxybutyrate Attenuates Cardiac Inflammation and Hepatic Fibrosis in Dahl Salt-Sensitive Rats. Current Issues in Molecular Biology. 2026;48(6):620. doi:10.3390/cimb48060620

BibTeX
@article{Ito2026,
  author = {Ito, Satoyasu and Manabe, Eri and Shikata, Toshiyuki and Takamoto, Kojiro and Kobuchi, Shuhei},
  title = {β-Hydroxybutyrate Attenuates Cardiac Inflammation and Hepatic Fibrosis in Dahl Salt-Sensitive Rats},
  journal = {Current Issues in Molecular Biology},
  year = {2026},
  volume = {48},
  number = {6},
  pages = {620},
  doi = {10.3390/cimb48060620}
}
Kostenlos starten →